• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

司美格鲁肽作用机制聚焦

Spotlight on the Mechanism of Action of Semaglutide.

作者信息

Papakonstantinou Ilias, Tsioufis Konstantinos, Katsi Vasiliki

机构信息

4th Department of Internal Medicine, Evangelismos General Hospital, 10676 Athens, Greece.

1st Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece.

出版信息

Curr Issues Mol Biol. 2024 Dec 23;46(12):14514-14541. doi: 10.3390/cimb46120872.

DOI:10.3390/cimb46120872
PMID:39728000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11674233/
Abstract

Initially intended to control blood glucose levels in patients with type 2 diabetes, semaglutide, a potent glucagon-like peptide 1 analogue, has been established as an effective weight loss treatment by controlling appetite. Integrating the latest clinical trials, semaglutide in patients with or without diabetes presents significant therapeutic efficacy in ameliorating cardiometabolic risk factors and physical functioning, independent of body weight reduction. Semaglutide may modulate adipose tissue browning, which enhances human metabolism and exhibits possible benefits in skeletal muscle degeneration, accelerated by obesity and ageing. This may be attributed to anti-inflammatory, mitochondrial biogenesis, antioxidant and autophagy-regulating effects. However, most of the supporting evidence on the mechanistic actions of semaglutide is preclinical, demonstrated in rodents and not actually confirmed in humans, therefore warranting caution in the interpretation. This article aims to explore potential innovative molecular mechanisms of semaglutide action in restoring the balance of several interlinking aspects of metabolism, pointing to distinct functions in inflammation and oxidative stress in insulin-sensitive musculoskeletal and adipose tissues. Moreover, possible applications in protection from infections and anti-aging properties are discussed. Semaglutide enhancement of the core molecular mechanisms involved in the progress of obesity and diabetes, although mostly preclinical, may provide a framework for future research applications in human diseases overall.

摘要

司美格鲁肽是一种强效胰高血糖素样肽1类似物,最初旨在控制2型糖尿病患者的血糖水平,现已被确认为一种通过控制食欲来有效减肥的治疗方法。综合最新的临床试验,司美格鲁肽在糖尿病患者和非糖尿病患者中,无论体重是否减轻,在改善心脏代谢危险因素和身体功能方面均具有显著的治疗效果。司美格鲁肽可能会调节脂肪组织褐变,这会增强人体新陈代谢,并对因肥胖和衰老而加速的骨骼肌退化表现出潜在益处。这可能归因于抗炎、线粒体生物合成、抗氧化和自噬调节作用。然而,关于司美格鲁肽作用机制的大多数支持证据都是临床前的,在啮齿动物中得到证实,但尚未在人体中实际得到确认,因此在解释时需要谨慎。本文旨在探索司美格鲁肽作用的潜在创新分子机制,以恢复代谢几个相互关联方面的平衡,指出其在胰岛素敏感的肌肉骨骼和脂肪组织的炎症和氧化应激中的独特功能。此外,还讨论了其在预防感染和抗衰老特性方面的可能应用。司美格鲁肽增强肥胖和糖尿病进展中涉及的核心分子机制,尽管大多是临床前的,但可能为未来人类疾病的研究应用提供一个框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/2c240b9f1e40/cimb-46-00872-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/a35a1d26002c/cimb-46-00872-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/116c7ebb4408/cimb-46-00872-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/2c240b9f1e40/cimb-46-00872-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/a35a1d26002c/cimb-46-00872-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/116c7ebb4408/cimb-46-00872-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9954/11674233/2c240b9f1e40/cimb-46-00872-g003.jpg

相似文献

1
Spotlight on the Mechanism of Action of Semaglutide.司美格鲁肽作用机制聚焦
Curr Issues Mol Biol. 2024 Dec 23;46(12):14514-14541. doi: 10.3390/cimb46120872.
2
Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy.司美格鲁肽(胰高血糖素样肽-1受体激动剂)治疗开始后基于CT的身体成分的患者内变化。
AJR Am J Roentgenol. 2024 Dec;223(6):e2431805. doi: 10.2214/AJR.24.31805. Epub 2024 Sep 4.
3
Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.司美格鲁肽(GLP-1 受体激动剂)可刺激皮下脂肪脂肪细胞的褐色化,并减轻肥胖小鼠内脏脂肪脂肪细胞的炎症和内质网应激。
Cell Biochem Funct. 2022 Dec;40(8):903-913. doi: 10.1002/cbf.3751. Epub 2022 Sep 28.
4
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.司美格鲁肽对超重伴胰岛素抵抗老年人身体功能、身体成分和衰老生物标志物的影响:一项开放标签随机对照试验方案。
JMIR Res Protoc. 2024 Sep 13;13:e62667. doi: 10.2196/62667.
5
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.每周一次司美格鲁肽对肥胖受试者的食欲、能量摄入、摄食控制、食物偏好和体重的影响。
Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5.
6
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.在患有代谢功能障碍相关脂肪性肝病的个体中,无论糖尿病和心脏代谢风险参数如何,司美格鲁肽均可带来相似的体重减轻:三项随机对照试验的事后分析
Diabetes Obes Metab. 2025 Feb;27(2):710-718. doi: 10.1111/dom.16065. Epub 2024 Nov 28.
7
Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes.六个月的司美格鲁肽治疗 2 型糖尿病可恢复脂肪祖细胞分化为代谢活跃脂肪细胞的潜能。
Eur J Pharmacol. 2024 May 5;970:176476. doi: 10.1016/j.ejphar.2024.176476. Epub 2024 Mar 15.
8
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.司美格鲁肽可改善超重或肥胖成年人的心血管代谢风险因素:STEP 1 和 4 探索性分析。
Diabetes Obes Metab. 2023 Feb;25(2):468-478. doi: 10.1111/dom.14890. Epub 2022 Oct 28.
9
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.每周一次司美格鲁肽治疗 2 型糖尿病的疗效和安全性。
Expert Opin Investig Drugs. 2017 Sep;26(9):1083-1089. doi: 10.1080/13543784.2017.1360274. Epub 2017 Aug 2.
10
Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.酰基辅酶A:胆固醇酰基转移酶1抑制剂与胰高血糖素样肽1受体激动剂联合给药对饮食诱导肥胖啮齿动物模型的影响
Biochem Biophys Res Commun. 2023 Dec 25;688:149164. doi: 10.1016/j.bbrc.2023.149164. Epub 2023 Nov 7.

引用本文的文献

1
Novel Drug Targets in Diastolic Heart Disease.舒张性心脏病的新型药物靶点
Int J Mol Sci. 2025 Aug 20;26(16):8055. doi: 10.3390/ijms26168055.
2
[Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].[通过胰高血糖素样肽-1受体激动剂实现的快速体重减轻作为一种生活方式现象及其对整形美容医学的影响]
HNO. 2025 Aug 6. doi: 10.1007/s00106-025-01653-w.
3
Misrepresentation of semaglutide in social media.司美格鲁肽在社交媒体上的失实陈述。

本文引用的文献

1
The 3 I's of immunity and aging: immunosenescence, inflammaging, and immune resilience.免疫与衰老的三个“ I ”:免疫衰老、炎症衰老和免疫弹性。
Front Aging. 2024 Oct 16;5:1490302. doi: 10.3389/fragi.2024.1490302. eCollection 2024.
2
Adipose Tissue Plasticity: A Comprehensive Definition and Multidimensional Insight.脂肪组织可塑性:全面定义和多维洞察。
Biomolecules. 2024 Sep 27;14(10):1223. doi: 10.3390/biom14101223.
3
The Impact of Gastrointestinal Hormones on Human Adipose Tissue Function.胃肠道激素对人体脂肪组织功能的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 19. doi: 10.1007/s00210-025-04403-5.
4
Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.度拉糖肽与司美格鲁肽对糖尿病患者肾功能下降和蛋白尿减少的比较效果:一项回顾性队列研究
J Clin Med. 2025 Jun 16;14(12):4287. doi: 10.3390/jcm14124287.
5
A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes.黄芪甲苷和小檗碱对肥胖及糖尿病相关血管功能障碍作用机制的研究综述
Drug Des Devel Ther. 2025 Jun 7;19:4911-4932. doi: 10.2147/DDDT.S520323. eCollection 2025.
6
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.司美格鲁肽作为一种胰高血糖素样肽-1(GLP-1)激动剂:肥胖治疗的一项突破。
Pharmaceuticals (Basel). 2025 Mar 12;18(3):399. doi: 10.3390/ph18030399.
Nutrients. 2024 Sep 25;16(19):3245. doi: 10.3390/nu16193245.
4
Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases.脂肪组织与其他器官相互作用中的脂肪因子:对心血管代谢疾病的影响
Biomedicines. 2024 Sep 19;12(9):2129. doi: 10.3390/biomedicines12092129.
5
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体:作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
6
The Role of Inflammatory Mediators in the Pathogenesis of Obesity.炎症介质在肥胖发病机制中的作用。
Nutrients. 2024 Aug 23;16(17):2822. doi: 10.3390/nu16172822.
7
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.司美格鲁肽对死亡率及新冠病毒相关死亡的影响:SELECT试验分析
J Am Coll Cardiol. 2024 Oct 22;84(17):1632-1642. doi: 10.1016/j.jacc.2024.08.007. Epub 2024 Aug 30.
8
Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance.脂肪组织:肠促胰岛素轴的新靶点?肥胖相关胰岛素抵抗的范式转变。
Int J Mol Sci. 2024 Aug 8;25(16):8650. doi: 10.3390/ijms25168650.
9
Cross-talks between perivascular adipose tissue and neighbors: multifaceted nature of nereids.血管周围脂肪组织与其相邻组织之间的相互作用:神经血管单元的多面性
Front Pharmacol. 2024 Aug 2;15:1442086. doi: 10.3389/fphar.2024.1442086. eCollection 2024.
10
Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-A Narrative Review.胰高血糖素样肽-1 受体激动剂对血清脂质、脂肪组织和肌肉代谢的影响:叙述性综述。
Int J Mol Sci. 2024 Jul 27;25(15):8214. doi: 10.3390/ijms25158214.